The forecast for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) medicine sales in Germany indicates a gradual decline from 2024 to 2028, starting at 575 million euros in 2024 and decreasing to 556.6 million euros by 2028. From 2024 onwards, the year-on-year decline is consistent, reaching approximately a 0.8% decrease annually.

Future trends to watch include:

Shifts in healthcare policy or reimbursement structures impacting patient access and medication affordability.
Growth in generic medicine adoption and competitive market pressures.
Advancements in alternative therapies or digital health interventions possibly decreasing demand for traditional medicines.
Demographic changes influencing the prevalence of these gastrointestinal conditions.